Evaluating a new ultrasound technique for diagnosing pancreatic cancer
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
GCS Ramsay Santé pour l'Enseignement et la Recherche · NCT04851106
This study is testing a new ultrasound technique to see if it can help doctors better diagnose pancreatic cancer in adults who have suspected tumors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | GCS Ramsay Santé pour l'Enseignement et la Recherche (other) |
| Locations | 1 site (Lyon) |
| Trial ID | NCT04851106 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the diagnostic accuracy of Shear Wave Elastography (SWE) using Endoscopic Ultrasound (EUS) for identifying pancreatic adenocarcinoma. Given the challenges in differentiating pancreatic cancer from other solid pancreatic lesions, the study seeks to improve diagnostic specificity and accuracy beyond current methods. Participants will undergo EUS with SWE to evaluate its effectiveness in diagnosing solid pancreatic masses of indeterminate origin. The study focuses on patients over 18 years of age with suspected pancreatic tumors.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a solid pancreatic mass of indeterminate origin.
Not a fit: Patients with severe comorbidities or contraindications to the procedure will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses of pancreatic cancer, potentially improving patient outcomes.
How similar studies have performed: While similar techniques have shown promise in other areas, this specific application of SWE for pancreatic cancer diagnosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years of age * Patient with a solid pancreatic mass of indeterminate origin Exclusion Criteria: * Patient with ASA score 4 or 5 * Patient with contraindication to SonoVue injection * Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
Where this trial is running
Lyon
- Hôpital Jean Mermoz — Lyon, France (RECRUITING)
Study contacts
- Principal investigator: Rodica GINCUL — Hôpital Jean Mermoz
- Study coordinator: Rodica GINCUL
- Email: rodica_h13@yahoo.fr
- Phone: 0615340869
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreas Cancer